Log in

NASDAQ:FPRX - Five Prime Therapeutics Stock Price, Forecast & News

$2.33
-0.23 (-8.98 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$2.30
Now: $2.33
$2.51
50-Day Range
$1.86
MA: $3.81
$5.36
52-Week Range
$1.75
Now: $2.33
$13.84
Volume250,482 shs
Average Volume411,769 shs
Market Capitalization$84.79 million
P/E RatioN/A
Dividend YieldN/A
Beta2.55
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; a collaboration agreement with Roche; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.
Read More
Five Prime Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FPRX
CUSIPN/A
Phone415-365-5600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$14.87 million
Book Value$4.13 per share

Profitability

Net Income$-137,200,000.00
Net Margins-922.43%

Miscellaneous

Employees209
Market Cap$84.79 million
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive FPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for FPRX and its competitors with MarketBeat's FREE daily newsletter.


Five Prime Therapeutics (NASDAQ:FPRX) Frequently Asked Questions

How has Five Prime Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Five Prime Therapeutics' stock was trading at $2.93 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FPRX stock has decreased by 20.5% and is now trading at $2.33. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Five Prime Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Five Prime Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Five Prime Therapeutics.

When is Five Prime Therapeutics' next earnings date?

Five Prime Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Five Prime Therapeutics.

How were Five Prime Therapeutics' earnings last quarter?

Five Prime Therapeutics Inc (NASDAQ:FPRX) posted its quarterly earnings results on Thursday, February, 27th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.97) by $0.08. The biotechnology company earned $3.21 million during the quarter, compared to analysts' expectations of $4.05 million. Five Prime Therapeutics had a negative net margin of 922.43% and a negative return on equity of 71.29%. View Five Prime Therapeutics' earnings history.

What price target have analysts set for FPRX?

6 analysts have issued 1 year target prices for Five Prime Therapeutics' stock. Their forecasts range from $5.00 to $24.00. On average, they expect Five Prime Therapeutics' share price to reach $12.25 in the next twelve months. This suggests a possible upside of 425.8% from the stock's current price. View analysts' price targets for Five Prime Therapeutics.

Has Five Prime Therapeutics been receiving favorable news coverage?

Media headlines about FPRX stock have been trending positive recently, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Five Prime Therapeutics earned a media sentiment score of 2.4 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutFive Prime Therapeutics.

Are investors shorting Five Prime Therapeutics?

Five Prime Therapeutics saw a decrease in short interest in the month of March. As of March 13th, there was short interest totaling 1,422,400 shares, a decrease of 10.5% from the February 27th total of 1,590,000 shares. Based on an average daily volume of 373,700 shares, the short-interest ratio is presently 3.8 days. Approximately 4.0% of the shares of the company are sold short. View Five Prime Therapeutics' Current Options Chain.

Who are some of Five Prime Therapeutics' key competitors?

What other stocks do shareholders of Five Prime Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Five Prime Therapeutics investors own include Nektar Therapeutics (NKTR), Novavax (NVAX), Gilead Sciences (GILD), TG Therapeutics (TGTX), Clovis Oncology (CLVS), Ionis Pharmaceuticals (IONS), Opko Health (OPK), Sangamo Therapeutics (SGMO), Amarin (AMRN) and Anavex Life Sciences (AVXL).

Who are Five Prime Therapeutics' key executives?

Five Prime Therapeutics' management team includes the following people:
  • Mr. Aron Marc Knickerbocker, Pres, CEO & Director (Age 50)
  • Mr. Francis W. Sarena, Chief Strategy Officer & Sec. (Age 48)
  • Dr. Helen Louise Collins, Sr. VP & Chief Medical Officer (Age 56)
  • Dr. Peder K. Jensen, Advisor & Director (Age 64)
  • Mr. David V. Smith, Exec. VP & CFO

What is Five Prime Therapeutics' stock symbol?

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

Who are Five Prime Therapeutics' major shareholders?

Five Prime Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BVF Inc. IL (21.39%), Renaissance Technologies LLC (4.84%), State Street Corp (1.72%), Man Group plc (1.50%), Geode Capital Management LLC (1.42%) and AQR Capital Management LLC (1.23%). Company insiders that own Five Prime Therapeutics stock include Andrew T Feldstein, Bvf Partners L P/Il, Franklin M Berger and Value Fund L P Biotechnology. View institutional ownership trends for Five Prime Therapeutics.

Which major investors are selling Five Prime Therapeutics stock?

FPRX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Nuveen Asset Management LLC, Assenagon Asset Management S.A., AXA, UBS Group AG, State Street Corp, Citigroup Inc., and Bank of New York Mellon Corp. View insider buying and selling activity for Five Prime Therapeutics.

Which major investors are buying Five Prime Therapeutics stock?

FPRX stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Renaissance Technologies LLC, AQR Capital Management LLC, Jacobs Levy Equity Management Inc., Acadian Asset Management LLC, Russell Investments Group Ltd., Platinum Investment Management Ltd., and Geode Capital Management LLC. Company insiders that have bought Five Prime Therapeutics stock in the last two years include Andrew T Feldstein, Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Five Prime Therapeutics.

How do I buy shares of Five Prime Therapeutics?

Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Five Prime Therapeutics' stock price today?

One share of FPRX stock can currently be purchased for approximately $2.33.

How big of a company is Five Prime Therapeutics?

Five Prime Therapeutics has a market capitalization of $84.79 million and generates $14.87 million in revenue each year. The biotechnology company earns $-137,200,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Five Prime Therapeutics employs 209 workers across the globe. View additional information about Five Prime Therapeutics.

What is Five Prime Therapeutics' official website?

The official website for Five Prime Therapeutics is http://www.fiveprime.com/.

How can I contact Five Prime Therapeutics?

Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600 or via email at [email protected]


MarketBeat Community Rating for Five Prime Therapeutics (NASDAQ FPRX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  290 (Vote Outperform)
Underperform Votes:  236 (Vote Underperform)
Total Votes:  526
MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote "Outperform" if you believe FPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: Catch-Up Contributions

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel